U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O4S.Zn
Molecular Weight 411.742
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC PHENOLSULFONATE

SMILES

[Zn++].OC1=CC=C(C=C1)S([O-])(=O)=O.OC2=CC=C(C=C2)S([O-])(=O)=O

InChI

InChIKey=ZNVKGUVDRSSWHV-UHFFFAOYSA-L
InChI=1S/2C6H6O4S.Zn/c2*7-5-1-3-6(4-2-5)11(8,9)10;/h2*1-4,7H,(H,8,9,10);/q;;+2/p-2

HIDE SMILES / InChI
Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
2002 Mar 1
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Name Type Language
ZINC PHENOLSULFONATE
HSDB   INCI   MART.   VANDF   WHO-DD  
INCI  
Official Name English
ZINC PHENOLSULFONATE [HSDB]
Common Name English
ZINC PHENOLSULPHONATE
Common Name English
ZINC PHENOLSULFONATE [INCI]
Common Name English
ZINC PARAPHENOLSULFONATE
Common Name English
Zinc phenolsulfonate [WHO-DD]
Common Name English
ZINC PARAPHENOLSULPHONATE
Common Name English
PHENOZIN
Brand Name English
ZINC P-PHENOLSULPHONATE
Common Name English
4-HYDROXYBENZENESULFONIC ACID (2:1), ZINC SALT
Common Name English
BENZENESULFONIC ACID, 4-HYDROXY-, ZINC SALT (2:1)
Systematic Name English
ZINC PHENOLSULFONATE [MART.]
Common Name English
P-HYDROXYBENZENESULFONIC ACID ZINC SALT
Common Name English
ZINC P-PHENOLSULFONATE [MI]
Common Name English
ZINC P-PHENOLSULFONATE
MI  
Common Name English
ZINC SULFOCARBOLATE
Common Name English
ZINC PHENOLSULFONATE [VANDF]
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 89002
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
NCI_THESAURUS C28394
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C84250
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
FDA UNII
4O71YT5YB5
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
SMS_ID
100000127775
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
ECHA (EC/EINECS)
204-867-8
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID1059571
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
HSDB
2551
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
DAILYMED
4O71YT5YB5
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
EVMPD
SUB33888
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
RXCUI
89831
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY RxNorm
CAS
127-82-2
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
PUBCHEM
31391
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY
MERCK INDEX
m11620
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
PRIMARY Merck Index
CAS
51136-97-1
Created by admin on Fri Dec 15 15:06:20 GMT 2023 , Edited by admin on Fri Dec 15 15:06:20 GMT 2023
NON-SPECIFIC STOICHIOMETRY